PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials

PIK3CA mutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA and, if possible, KRAS mut...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Janku, Filip, Wheler, Jennifer J., Naing, Aung, Falchook, Gerald S., Hong, David S., Stepanek, Vanda M., Fu, Siqing, Piha-Paul, Sarina A., Lee, J. Jack, Luthra, Rajyalakshmi, Tsimberidou, Apostolia M., Kurzrock, Razelle
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537862/
https://ncbi.nlm.nih.gov/pubmed/23066039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-1726
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky